DPP4 and diabetic kidney disease: For example, linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor and FDA-approved glucose-lowering drug for type 2 diabetes, have shown reno-protective effects in rodent models of both non-diabetic as well as diabetic kidney disease [184].